PracSys of Salem, NH, last month entered a claim with the American Arbitration Association against North American Scientific regarding a linear accelerator supply deal between the companies that broke down. PracSys filed the complaint on June 16, after
PracSys of Salem, NH, last month entered a claim with the American Arbitration Association against North American Scientific regarding a linear accelerator supply deal between the companies that broke down. PracSys filed the complaint on June 16, after its attempts to resolve a contract dispute with NASI failed.
PracSys and North American Scientific signed a supply deal last year in which North American agreed to pay PracSys $2.7 million for two linear accelerators (SCAN 3/4/98). North American Scientific planned to use the accelerators to produce palladium-103 for the manufacture of prostate brachytherapy seeds.
But the partnership soured six months ago, according to PracSys. The companys complaint states that after the agreement with North American Scientific was signed, NASI signed a contract with another vendor for the supply of palladium, and reneged on its obligation to provide a lease guaranty crucial to the PracSys deal. PracSys claims that North American Scientifics actions prevented it from fulfilling its contract, and the company seeks damages of $3 million.
PracSys claim is meritless, North American Scientific executives told SCAN. In a statement also released June 16, the Chatsworth, CA, company declared that it has realized its obligations under the 1998 contract with PracSys, and announced that it has asked PracSys to turn over the uncompleted linear acceleratorsfor which NASI claims it has paid in full. North American Scientific will install and finish them itself, the company said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.